ArticleBMC nursing2025
Effects of a Salutogenic Model-Based Frailty Prevention Program (SAFRAPP) in pre-frail women: a randomized controlled trial.
Article in BMC nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04787432 (The Effect of Salutogenic Model Based Frailty Prevention Program on Development of Frailty and Sense of Coherence in Women Aged 55 Years and Over), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Salutogenic Model Based Frailty Prevention Program on Development of Frailty and Sense of Coherence in Women Aged 55 Years and Over
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty is a geriatric syndrome characterized by increased vulnerability to stressors and is more prevalent among women. As a dynamic condition, its progression can be prevented through early interventions. Therefore, this study aimed to evaluate the effect of Salutogenic Model-Based Frailty Prevention Program (SAFRAPP) among pre-frail women on preventing development of frailty and improving sense of coherence (SOC).
methodsA single-blinded, two-arm randomized controlled trial was conducted with a total of 84 pre-frail women aged 55 years and older. Participants were randomly assigned to the intervention group (n = 42) or the control (n = 42) groups. SAFRAPP was implemented in the intervention group for six weeks and consisted of health education, case management, and laughter yoga. The primary outcomes were frailty status and SOC. Secondary outcomes were well-being, quality of life, fear of falling, number of falls, and emergency visits. Data were collected at baseline and at 3-month, 6-month, and 9-month follow-ups from both groups. Pearson’s chi-square test, independent samples t-test and repeated measures analysis of variance were used for data analysis.
resultsThe results revealed that nearly half of the pre-frail women in the intervention group transitioned to a robust stage, showing a statistically significant improvement compared to the control group at the 3-month, 6-month, and 9-month follow-ups (p < 0.001). The intervention group showed a significant improvement in SOC and well-being at the 3-month, 6-month, and 9-month follow-ups (p < 0.001). There was a significant improvement in quality of life and a reduction in fear of falling between baseline, 3-month, and 6-month assessments. However, the SAFRAPP group showed no significant change in falls and emergency visits over time compared to the control group (p > 0.05).
conclusionsA nurse-led multicomponent intervention based on the Salutogenic Model appears to be effective in preventing the progression of frailty, improving sense of coherence, well-being, and quality of life among women aged 55 years and older. Future studies should investigate the potential for SAFRAPP in diverse populations and healthcare settings.
trial registrationClinicalTrials.gov Identifier: NCT04787432, date of registration: 08/03/2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.